|Generic name||Daratumumab and hyaluronidase-fihj|
|Brand name(s), other common name(s)||Darzalex FasproTM|
|Drug type||Monoclonal antibody|
|How the drug is given||Injection, for subcutaneous use|
Indications and Usage
Darzalex FasproTM is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, and is FDA approved for the treatment of adult patients with multiple myeloma:
- In combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant
- In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy
- In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy
- As monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.
Side effects needing medical attention
The most common adverse reaction is: upper respiratory tract infection
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.